Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms.
about
A Frailty Index Based On Deficit Accumulation Quantifies Mortality Risk in Humans and in Mice.Nutrition, metabolism, and targeting aging in nonhuman primates.Cellular Senescence: A Translational Perspective.The Clinical Potential of Senolytic Drugs.Circulating levels of monocyte chemoattractant protein-1 as a potential measure of biological age in mice and frailty in humans.Spontaneous DNA damage to the nuclear genome promotes senescence, redox imbalance and aging.
P2860
Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 August 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms.
@en
Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms.
@nl
type
label
Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms.
@en
Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms.
@nl
prefLabel
Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms.
@en
Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms.
@nl
P2093
P2860
P356
P1476
Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms.
@en
P2093
Christin E Burd
James L Kirkland
Laura J Niedernhofer
Matthew S Gill
Nir Barzilai
Paul D Robbins
Steven N Austad
P2860
P304
P356
10.1093/GERONA/GLW112
P407
P577
2016-08-16T00:00:00Z